Gene therapy injection tested in Real-World fight against debilitating muscle disease

NCT ID NCT07448610

Summary

This study aims to gather real-world evidence on the safety and effectiveness of a one-time spinal injection gene therapy (ITVISMA®) for people with Spinal Muscular Atrophy (SMA). It will follow 36 U.S. participants, aged 2 and older, for at least a year after their treatment to see how their motor function and quality of life change. The study will also track side effects and how the treatment impacts healthcare needs like hospital visits and breathing support.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Conditions

Explore the condition pages connected to this study.